

1 **Brief Report**

2 **SARS-CoV-2 antibody responses in children with MIS-C and mild and severe**  
3 **COVID-19**

4 Elizabeth M. Anderson<sup>1,12</sup>, Caroline Diorio<sup>2,3,12</sup>, Eileen C. Goodwin<sup>1</sup>, Kevin O. McNerney<sup>2,3</sup>,  
5 Madison E. Weirick<sup>1</sup>, Sigrid Gouma<sup>1</sup>, Marcus J. Bolton<sup>1</sup>, Claudia P. Arevalo<sup>1</sup>, Julie Chase<sup>2,4</sup>,  
6 Philip Hicks<sup>15</sup>, Tomaz B. Manzoni<sup>1</sup>, Amy E. Baxter<sup>6,7</sup>, Kurt P. Andrea<sup>6,7</sup>, Chakkapong  
7 Burudpakdee<sup>2</sup>, Jessica H. Lee<sup>2</sup>, Laura A. Vella<sup>6,7,8</sup>, Sarah E. Henrickson<sup>9</sup>, Rebecca M. Harris<sup>10</sup>,  
8 E. John Wherry<sup>6,7</sup>, Paul Bates<sup>1,11</sup>, Hamid Bassiri<sup>2,8</sup>, Edward M. Behrens<sup>2,4</sup>, David T. Teachey<sup>2,3</sup>,  
9 and Scott E. Hensley<sup>1,\*</sup>

10

11 <sup>1</sup>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,  
12 Philadelphia, PA USA; <sup>2</sup>Immune Dysregulation Frontier Program, Department of Pediatrics,  
13 Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine,  
14 Philadelphia, PA, USA; <sup>3</sup>Division of Oncology, Department of Pediatrics, Children's Hospital of  
15 Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA;  
16 <sup>4</sup>Division of Rheumatology, Department of Pediatrics, Children's Hospital of Philadelphia,  
17 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; <sup>5</sup>School of  
18 Veterinary Medicine, University of Pennsylvania, Philadelphia, PA USA; <sup>6</sup>Institute for  
19 Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,  
20 USA; <sup>7</sup>Department of Systems Pharmacology and Translational Therapeutics, University of  
21 Pennsylvania, Philadelphia, PA, USA; <sup>8</sup>Division of Infectious Diseases, Department of  
22 Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of  
23 Medicine, Philadelphia, PA, USA; <sup>9</sup>Division of Allergy and Immunology, Department of  
24 Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of  
25 Medicine, Philadelphia, PA, USA; <sup>10</sup>Department of Pathology and Laboratory Medicine,  
26 Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine,  
27 Philadelphia, PA, USA; <sup>11</sup>Penn Center for Research on Coronavirus and Other Emerging  
28 Pathogens, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA;  
29 <sup>12</sup>These authors contributed equally to this work: Elizabeth M. Anderson and Caroline Diorio

30

31 \*Correspondence: [hensley@pennmedicine.upenn.edu](mailto:hensley@pennmedicine.upenn.edu)

32 **Key Words**

33 COVID-19; Pediatric; Antibodies; Multisystem Inflammatory Syndrome in Children (MIS-C);  
34 SARS-COV-2

35 **ABSTRACT (48 words)**

36 SARS-CoV-2 antibody responses in children remain poorly characterized. Here, we show that  
37 pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher  
38 SARS-CoV-2 spike IgG titers compared to those with severe coronavirus disease 2019 (COVID-  
39 19), likely reflecting a longer time since onset of infection in MIS-C patients.

40

41 **MAIN TEXT**

42 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) manifests differently in  
43 pediatric populations. While the absolute numbers and rate of development of severe coronavirus  
44 disease 2019 (COVID-19) is significantly lower in children compared to adults (1), some  
45 pediatric patients develop severe to critical illness. Unlike adults, pediatric patients can also  
46 become afflicted with multisystem inflammatory syndrome in children (MIS-C) (2, 3). MIS-C is  
47 a syndrome that affects previously healthy children and manifests as a hyperinflammatory  
48 syndrome with multiorgan involvement that has some overlapping clinical features with  
49 Kawasaki disease shock syndrome (4-9). While it is believed that MIS-C represents a post-  
50 infectious sequela of SARS-CoV-2, the pathophysiology of this syndrome has not yet been  
51 delineated.

52 We sought to determine the humoral responses to SARS-CoV-2 in children presenting  
53 with COVID-19 vs. MIS-C to help illuminate potential pathophysiologies induced by the virus.  
54 We analyzed serum samples from 29 SARS-CoV-2 infected children admitted to the Children's  
55 Hospital of Philadelphia (CHOP) in April and May 2020 (Supplementary table S1). We  
56 categorized these patients into three clinical disease phenotypes: minimal COVID-19  
57 (asymptomatic children, or those with minimal symptoms; n=10), severe COVID-19 (children  
58 requiring invasive respiratory support or an increase in positive pressure ventilation above their  
59 baseline; n=9), and those with MIS-C (children meeting Centers for Disease Control criteria (2,  
60 10, 11); n=10). Detailed case studies of 6 of the 10 children with MIS-C (CD12, CD18, CD19,  
61 CD22, CD24, and CD26) were previously reported by our group (7). As expected, cycle  
62 threshold (Ct) values of SARS-CoV-2 RT-PCR were significantly lower in the pediatric patients  
63 presenting with severe COVID-19 (median: 28, IQR: 26 – 29) compared to children with MIS-C

64 (p=0.002 in one-way ANOVA) (Supplementary table S1). Similar to other reports (3), we found  
65 that children with SARS-CoV-2 had systemic inflammation evidenced by elevated inflammatory  
66 markers, including ESR, CRP, ferritin, and D-dimer (10). The severe COVID-19 and MIS-C  
67 patients also displayed elevated pro- and anti-inflammatory plasma cytokines (4, 5, 8). Finally,  
68 B-type natriuretic protein (BNP), a marker of cardiac inflammation, was higher in the MIS-C  
69 group versus the severe COVID-19 group, with the difference approaching statistical  
70 significance (Supplementary table S1).

71 We performed ELISAs to measure serum IgG antibodies against the SARS-CoV-2 full-  
72 length spike protein (S), the receptor binding domain (S-RBD) of the S protein (12, 13), and the  
73 nucleocapsid (N) protein (Figure 1A-C). We found that children in the minimal COVID-19  
74 cohort had varied levels of serum IgG against all SARS-CoV-2 antigens tests (Figure 1), which  
75 likely reflects the clinical heterogeneity of these patients. These patients were either completely  
76 asymptomatic with respect to SARS-CoV-2 (n=2), or were admitted for treatment of another  
77 infection (n=3). In contrast, we found that the majority of children with severe COVID-19 had  
78 undetectable levels of SARS-CoV-2 S, S-RBD, and N IgG antibodies (Figure 1A-C). This  
79 observation stands in contrast to that in adults with severe COVID-19, who typically possess  
80 higher levels of SARS-CoV-2 antibodies compared to adults with milder disease (14, 15). We  
81 found that patients with MIS-C had higher IgG antibody titers against S-RBD and full-length S  
82 (p=0.010 and p=0.025 in one-way ANOVA, respectively) compared to children with severe  
83 COVID-19 (Figure 1C). Children with MIS-C also had elevated levels of serum anti-SARS-  
84 CoV-2 N antibodies; however, this was not significantly higher than children with minimal or  
85 severe disease. We also performed ELISAs to measure serum IgM and IgA antibodies against  
86 the SARS-CoV-2 S, S-RBD, and N proteins (Figure 1D-I). Unlike IgG titers, we found no

87 statistically significant differences in IgM antibody titers between children with different SARS-  
88 CoV-2 diseases. We found that children with MIS-C had higher IgA antibody titers compared to  
89 children with severe COVID-19 against full-length S but not S-RBD ( $p=0.010$  in one-way  
90 ANOVA).

91 To measure levels of functional antibodies in pediatric patients, we also performed  
92 neutralization assays using pseudo-typed vesicular stomatitis virus (VSV) expressing the SARS-  
93 CoV-2 S protein (Figure 1J). Neutralization antibody titers highly correlated with IgG titers to  
94 full length S, S-RBD, and N ( $R^2=0.586, 0.632, \text{ and } 0.4643$ , respectively; Figure 1K). We found  
95 that children who presented with minimal disease had variable levels of neutralizing SARS-CoV-  
96 2 antibodies (Figure 1J). Children with MIS-C had higher neutralization titers compared to  
97 children with severe COVID-19 (Figure 1J), which is consistent with higher serum IgG titers  
98 against full length S (Figure 1A) and S-RBD (Figure 1B) in MIS-C children.

99 Collectively, our study suggests that children with MIS-C have higher levels of IgG  
100 antibodies that neutralize SARS-CoV-2 more effectively compared to children with severe  
101 COVID-19. Although this observation will require further study, we suspect that this finding  
102 may be due to a longer time since onset of infection in children with MIS-C relative to children  
103 with severe COVID-19. We could not formally investigate this possibility, since many of the  
104 patients in the MIS-C cohort did not recall a specific exposure or disease symptoms. Our  
105 previous studies indicate that adults with severe COVID-19 possess higher titers of SARS-CoV-  
106 2 S-RBD antibodies compared to adults with milder disease (14, 15). It is interesting that only 2  
107 of 9 pediatric patients with severe COVID-19 had detectable IgG antibody titers against the S-  
108 RBD protein. One of these seropositive patients presented with severe COVID-19 associated  
109 acute respiratory distress syndrome (ARDS) in the setting of pre-existing hypertension, insulin-

110 dependent diabetes mellitus and hypertrophic cardiomyopathy and eventually died from cardiac  
111 causes (Diorio et al, 2020 in press). The other seropositive patient had a history of adrenal  
112 insufficiency due to panhypopituitarism and presented with hypotension leading to respiratory  
113 failure, in the setting of multiple co-infections including rhinovirus, adenovirus, and a  
114 radiologically confirmed osteomyelitis. Further studies are required to determine why children  
115 with severe COVID-19 tend to have lower titers of SARS-CoV-2 antibodies compared to adults  
116 with similar disease.

## 117 **METHODS**

### 118 **Study participants**

119 We enrolled patients based on evidence of past or active SARS-CoV-2 infection (by positive RT-  
120 PCR in blood, stool or mucosa, the presence of serum IgG to SARS-CoV-2) or a very high  
121 clinical suspicion of MIS-C (10). Patients were categorized into three diseases phenotypes (MIS-  
122 C, severe COVID-19, or minimal COVID-19) after enrollment into the study. Patients were  
123 categorized as having MIS-C per the CDC case definition of MIS-C (11). Patients who presented  
124 with a primarily respiratory process requiring an increase in positive pressure support above their  
125 baseline and did not meet the criteria for MIS-C were categorized as “severe COVID-19”.  
126 Patients were classified as “minimal COVID-19” if they required hospitalization but did not  
127 otherwise meet criteria for MIS-C or severe COVID-19. Co-infections were identified by chart  
128 review for microbiologically proven infections that were deemed clinically significant by a panel  
129 of infectious disease physicians. This study was approved by the institutional review board at the  
130 Children’s Hospital of Philadelphia. Verbal informed consent was obtained from patients or their  
131 guardians in accordance with the Declaration of Helsinki. Due to the COVID-19 pandemic,

132 verbal consent was obtained and written consent was signed by the consenting physician. All  
133 participants were provided with a paper copy of the consent form.

134

### 135 **Detection of SARS-CoV-2 Nucleic Acid**

136 A real time-PCR assay for SARS-CoV-2 RNA was performed in a CLIA certified high-  
137 complexity clinical laboratory using a laboratory developed test with emergency use  
138 authorization from the FDA. The assay contained a primer/probe set for amplification and  
139 detection of the N2 gene of SARS-CoV-2 multiplexed with a primer/probe set for amplification  
140 of human  $\beta$ -actin as an internal control. RNA extraction from clinical samples was performed  
141 using the Roche MagNA Pure LC Total Nucleic Acid automated extraction platform. RT-PCR  
142 was performed using the Applied Biosystems Quant Studio DX using TaqMan chemistry. In this  
143 method, if a target is present, an increase in fluorescence during thermocycling is detected due to  
144 DNA polymerase cleavage of a TaqMan probe when the probe is bound, separating reporter and  
145 quencher dyes. A test is positive if measured fluorescence crosses a defined threshold above  
146 background levels, and the cycle threshold (Ct) is the number of cycles required for this to occur.  
147 Generally, the greater the amount of target nucleic acid present in the sample, the lower the Ct. A  
148 Ct of 45 or lower for the SARS-CoV-2 N2 target was defined as a positive result.

149

### 150 **Quantification of SARS-CoV-2 serum antibody titers**

151 Serum IgG, IgM, and IgA antibody titers against SARS-CoV-2 antigens were quantified by  
152 enzyme-linked immunosorbent assays (ELISA) as previously described (13). Plasmids encoding  
153 the full-length SARS-CoV-2 spike (S) protein and the receptor binding domain (S-RBD) were  
154 provided by Florian Krammer (Icahn School of Medicine at Mt. Sinai, New York City NY).

155 SARS-CoV-2 S-RBD and the full-length S proteins were purified from 293F transfected cells by  
156 Ni-NTA resin. SARS-CoV-2 nucleoprotein (N) was purchased (Sino Biological; Chesterbrook  
157 PA) and reconstituted in Dulbecco's phosphate buffered saline (DPBS). In brief, 200  $\mu$ L of  
158 blocking buffer (DPBS supplemented with 3% milk and 0.1% Tween-20) was added to ELISA  
159 plates (Immulon 4 HBX, Thermo Fisher Scientific, Waltham MA) that were washed three times  
160 with PBS plus 2% Tween (PBS-T) after being coated overnight at 4°C with 2  $\mu$ g/mL SARS-  
161 CoV-2 antigens. Sera were heat-inactivated prior to serial dilutions starting at 1:50 in dilution  
162 buffer (DPBS supplemented with 1% milk and 0.1% Tween-20). After blocking, ELISA plates  
163 were washed 3 times with PBS-T and 50  $\mu$ L of diluted sera was added. After 2 hours of  
164 incubation, ELISA plates were washed 3 times with PBS-T and 50 $\mu$ L of secondary antigen at  
165 1:5000 dilution (IgG; Jackson ImmunoResearch Laboratories; West Grove PA), 1:1000 (IgM;  
166 SouthernBiotech; Birmingham AL), or 1:500 (IgA; SouthernBiotech; Birmingham AL) in  
167 dilution buffer was added. ELISA plates were incubated for 1 hour, washed again 3 times with  
168 300 $\mu$ L PBS-T, and developed by adding 50  $\mu$ L of SureBlue tetramethylbenzidine substrate  
169 (SeraCare; Milford MA) and stopping the reaction with 25  $\mu$ L of 250 mM HCl after 5 minutes.  
170 Optical densities at 450 nm wavelength were obtained on a SpectraMax 190 microplate reader  
171 (Molecular Devices, San Jose CA). Serum antibody titers were expressed as the reciprocal serum  
172 dilution at a set OD that was based off of a standard curve from the monoclonal antibody  
173 CR3022 starting at 0.5  $\mu$ g/mL (for RBD and S ELISAs) or serially diluted pooled serum from  
174 actively SARS-CoV-2 infected adults (for N ELISAs). The plasmids to express CR3022 were a  
175 provided by Ian Wilson (Scripps Research Institute, San Diego CA). Standard curves were  
176 included on every plate to control for plate-to-plate variation.  
177



178 **Production of VSV pseudotypes with SARS-CoV-2 S for neutralization assays**

179 293T cells plated 24 hours previously at  $5 \times 10^6$  cells per 10 cm dish were transfected using  
180 calcium phosphate with 35 $\mu$ g of pCG1 SARS-CoV S delta18 expression plasmid encoding a  
181 codon optimized SARS-CoV S gene with an 18 residue truncation in the cytoplasmic tail (kindly  
182 provided by Stefan Pohlmann (German Primate Center, Göttingen, DE). 12 hours post  
183 transfection the cells were fed with fresh media containing 5mM sodium butyrate to increase  
184 expression of the transfected DNA. 30 hours after transfection, the SARS-CoV-2 spike  
185 expressing cells were infected for 2-4 hours with VSV-G pseudo-typed VSV $\Delta$ G-RFP at an MOI  
186 of  $\sim$ 1-3. After infection, the cells were washed twice with media to remove unbound virus.  
187 Media containing the VSV $\Delta$ G-RFP SARS-CoV-2 pseudo-types was harvested 28-30 hours after  
188 infection and clarified by centrifugation twice at 6000g then aliquoted and stored at -80°C until  
189 used for antibody neutralization analysis.

190

191 **Antibody neutralization assay using VSV $\Delta$ G-RFP SARS-CoV-2**

192 All sera were heat-inactivated for 1 hour at 55°C prior to use in neutralization assay. Vero E6  
193 cells stably expressing TMPRSS2 were seeded in 100  $\mu$ l at  $2.5 \times 10^4$  cells/well in a 96 well  
194 collagen coated plate. The next day, 2-fold serially diluted serum samples were mixed with  
195 VSV $\Delta$ G-RFP SARS-CoV-2 pseudo-type virus (50-200 focus forming units/well) and incubated  
196 for 1hr at 37°C. Also included in this mixture to neutralize any potential VSV-G carryover virus  
197 was 1E9F9, a mouse anti-VSV Indiana G, at a concentration of 600 ng/ml (Cat#Ab01402-2.0,  
198 Absolute Antibody, Oxford, UK). The serum-virus mixture was then used to replace the media  
199 on VeroE6 TMPRSS2 cells. 23-24 hours post infection, the cells were washed and fixed with 4%  
200 paraformaldehyde before visualization on an S6 FluoroSpot Analyzer (CTL, Shaker Heights

201 OH). Individual infected foci were enumerated and the values compared to control wells without  
202 antibody. The focus reduction neutralization titer 50% (FRNT<sub>50</sub>) was measured as the greatest  
203 serum dilution at which focus count was reduced by at least 50% relative to control cells that  
204 were infected with pseudo-type virus in the absence of patient serum. FRNT<sub>50</sub> titers for each  
205 sample were measured in at least two technical replicates performed on separate days.

206

### 207 **Statistical analysis**

208 Reciprocal serum dilution antibody titers were log<sub>2</sub> transformed for statistical analysis. ELISA  
209 antibody titers below the limit of detection were set to a reciprocal titer of 25. Log<sub>2</sub> transformed  
210 antibody titers were compared with one-way ANOVAs and unpaired t-tests. Statistical  
211 significance was set to p-value <0.05. Linear regressions were also performed using log<sub>2</sub>  
212 transformed titers and untransformed data from the other variables. Statistical analyses were  
213 performed using Prism version 8 (GraphPad Software, San Diego CA).

### 214 **DATA AVAILABILITY**

215 All data are included in the manuscript.

### 216 **ACKNOWLEDGEMENTS**

217 EMA and TBM were supported by the NIH Training in Virology T32 Program through grant  
218 number T32-AI-007324. PH was supported by the NIH Emerging Infectious Diseases T32  
219 Program T32AI055400. PB was supported by a Peer Reviewed Medical Research Program  
220 award PR182551 and grants from the NIH (R21AI129531 and R21AI142638). This work was  
221 supported by institutional funds from the University of Pennsylvania. We thank the COVID-19  
222 Processing Unit (CPU) at the University of Pennsylvania for receiving and processing sera

223 samples. We thank Jeffrey Lurie and we thank Joel Embiid, Josh Harris, David Blitzer for  
224 philanthropic support.


225

## 226 **COMPETING INTERESTS**

227 SEH has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work  
228 unrelated to this report.

229

Figure 1



231 **Figure Legend**

232

233 **Figure 1. Serum SARS-CoV-2 antibody levels in pediatric COVID-19 patients.** Antibody  
234 titers expressed as reciprocal serum dilution against SARS-CoV-2 antigens in pediatric patients  
235 with minimal disease (n=10), severe disease (n=9) and multisystem inflammatory syndrome  
236 (MIS-C; n=10). Line and error bars represent median antibody titer and interquartile range per  
237 disease phenotype. Titers against the SARS-CoV-2 receptor binding domain (S-RBD) IgG (a),  
238 IgM (d), and IgA (g). Titers against SARS-CoV-2 full length spike protein (S) IgG (b), IgM (e),  
239 and IgA (h). Titers against SARS-CoV-2 nucleocapsid protein (N) IgG (c) and IgM (f) and IgA  
240 (i). Note: IgA S and N antibodies were measured in a subset of samples with sufficient volume;  
241 N=23). (j) Neutralization activity of sera against SARS-CoV-2 spike pseudo-typed vesicular  
242 stomatitis virus (VSV) expressed as the geometric mean of the reciprocal dilution foci reduction  
243 neutralization titer (GMT FRNT; N=24). (k) Linear regressions of Log<sub>2</sub> transformed SARS-  
244 CoV-2 IgG titers (S, S-RBD, and N) and FRNT neutralization titers. Dashed lines denote the  
245 lower limit of detection at a reciprocal dilution of 50. Unpaired t-test of log<sub>2</sub> transformed titers  
246 \*\*p<0.001.

247

248

249

		Minimal N=10	Severe N=9	MISC-C N=10	
Age in years [IQR]		14 [3.5-16.5]	16 [14-17]	8.5 [6-14]	
Presence of Co-infection, N (%)		3 (38) <sup>a</sup>	4 (44) <sup>b</sup>	3 (30) <sup>c</sup>	
ICU Admission, N (%)		1 (12)	9 (100)	7 (70)	
Respiratory support*, N (%)		0 (0)	9 (100)	4 (40)	
Inotropic support, N, (%)		0 (0)	7 (78)	7 (70)	
SARS-CoV-2 RT-PCR (Ct)		34 [22-40]	28 [26-29]	38 [35-40]	
SARS-CoV-2 antibody titers (reciprocal dilution)	S-RBD	IgG	91 [<50-3624]	<50 [<50-304]	3532 [982-8677]
		IgM	129 [<50-433]	<50 [<50-424]	140 [<50-389]
		IgA	<50 [<50-1026]	<50 [<50-55]	69 [<50-3590]
	S	IgG	227 [<50-9716]	<50 [<50-1039]	7982 [1862-19597]
		IgM	113 [<50-650]	166 [<50-602]	138 [<50-307]
		IgA	163 [<50-2106]	<50 [<50-135]	3015 [240-6814]
	N	IgG	251 [139-1853]	<50 [<50-4843]	2140 [604-3713]
		IgM	<50 [<50-<50]	<50 [<50-573]	<50 [<50-<50]
		IgA	<50 [<50-101]	<50 [<50-<50]	<50 [<50-124.5]
Ferritin		NT	677 [181-9860]	804 [686-892]	
D-dimer		NT	2.5 [0.8-20.5]	5.8 [3.5-20.5]	
C-reactive protein		18.3 [14.6-25.5]	30.9 [7.0-34.9]	21.7 [19.1-33.0]	
ESR		51 [42-93]	20 [13-33]	68 [40-82]	
BNP		NT	395 [46.8-671]	1003 [377-1554]	

250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261

**Supplemental Table S1. Comparative clinical features and laboratory data for each pediatric SARS-CoV-2 cohort.** Data are presented as median [IQR]; \*Included intubation with ventilation or non-invasive positive pressure ventilation; <sup>a</sup> Co-infections included *Staphylococcus aureus* osteomyelitis (N=2, with 1 of 2 also with bacteremia), *Salmonella enteritis* (N=1); <sup>b</sup> Co-infections included *E. coli* bacteremia (N=1), Enterovirus meningitis (N=1), Adenovirus, Rhinovirus, and calvarial osteomyelitis (N=1), and *E.coli* urinary tract infection (N=1); <sup>c</sup> Co-infections included Parainfluenza virus infection (N=1), possible Epstein-barr virus with positive IgM (N=1) and Rhinovirus infection (N=1); NT - not tested. Data were not available for all patients.

## REFERENCES

1. J. F. Ludvigsson, Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* **109**, 1088-1095 (2020).
2. C. C.-R. Team, Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* **69**, 422-426 (2020).
3. W. Liu *et al.*, Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *N Engl J Med* **382**, 1370-1371 (2020).
4. S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, P. Theocharis, Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* **395**, 1607-1608 (2020).
5. L. Verdoni *et al.*, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* **395**, 1771-1778 (2020).
6. C. Galeotti, J. Bayry, Autoimmune and inflammatory diseases following COVID-19. *Nat Rev Rheumatol* 10.1038/s41584-020-0448-7 (2020).
7. K. Chiotos *et al.*, Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series. *J Pediatric Infect Dis Soc* 10.1093/jpids/piaa069 (2020).
8. E. M. Dufort *et al.*, Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med* 10.1056/NEJMoa2021756 (2020).
9. L. R. Feldstein *et al.*, Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med* 10.1056/NEJMoa2021680 (2020).
10. C. Diorio *et al.*, Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. *J Clin Invest* 10.1172/jci140970 (2020).

11. CDC (2020) Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19).
12. F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 10.1038/s41591-020-0913-5 (2020).
13. D. D. Flannery *et al.*, SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci Immunol* **5** (2020).
14. L. Kuri-Cervantes *et al.*, Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci Immunol* **5** (2020).
15. D. Mathew *et al.*, Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* 10.1126/science.abc8511 (2020).